Five years after being co-founded by UCL researchers, Ori Biotech has brought its overall funding to $41m.

Novo-backed congenital adrenal hyperplasia drug developer Spruce Biosciences has added approximately $14m to close its initial public offering.

The personalised medicine technology provider hiked its overall funding to $115m, with Cardinal Health, McKesson Ventures and Novartis all backing a series C extension.

The protein drug developer has now secured more than $195m in total, its earlier backers including GlaxoSmithKline, Pfizer, Eli Lilly and Schrödinger.

Cancer drug developer ImmuneOnco has caught the attention of Eli Lilly's Asia-focused vehicle and will put the series B proceeds toward clinical trials.

Alphabet subsidiary GV led a $16.5m series A round for the healthcare revenue management startup that followed a $6m round last year.

Novartis Venture Fund and Novo Seeds co-led a $10.4m round for oncology therapy developer Rappta on behalf of corporate parents Novartis and Novo.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Alexandria Real Estate Equities-backed oncology therapy developer is floating in the middle of its range to raise $82.5m in its initial public offering.

Eli Lilly participated in a $57.6m round that will support the identification and preclinical development of Cedilla's first two small molecule product candidates.